Clinical trial NCT03395392: NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
Official title: A Randomized, Double-Blind Controlled Comparison of NRX-101 to Lurasidone for Adults With Bipolar Depression and Subacute Suicidal Ideation or Behavior
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Bipolar Depression
Suicidal Ideation and Behavior
Keywords: Bipolar
Cyloserine
Lurasidone
MADRS
CGI-SS
C-SSRS
Lead sponsor: NeuroRx, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Prevail Infoworks
First posted: 2018-01-10
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in the treatment of bipolar depression with suicidal ideation. This study will test the hypothesis that NRX-101 is superior to lurasidone alone (standard of care) in maintaining remission from symptoms of depression (primary endpoint) and suicidal ideation or behavior (declared secondary endpoint) over a six week period of twice-daily oral dosing.

Detailed description: Background and Rationale: NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NRX-101 is composed of D-cycloserine (DCS) an NMDA antagonist and lurasidone (5HT2a atypical antipsychotic and antidepressant). In a phase 2 clinical study of bipolar depression and acute suicidal ideation and behavior, (in patients requiring hospitalization) patients received an initial infusion of ketamine and then NRX-101 for 6 weeks. In that phase 2 study, NRX-101 showed the ability to maintain remission from depression and suicidality over 6 weeks when taken twice daily. In this current out patient study, patients with bipolar depression and subacute suicidality (not requiring hospitalization), ketamine will not be used.

Primary Objective:

* To test the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in improving symptoms of depression as measured by the total Montgomery Åsberg Depression Rating Scale (MADRS-10) score in patients with bipolar depression and subacute suicidal ideation and behavior (SSIB) which does not require hospitalization.

Secondary Objectives:

• To test the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in reducing suicidality in depressed bipolar patients with SSIB, as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)

Methodology: : A multi-center, randomized, double-blind, trial in which patients with bipolar depression (MADRS ≥30) and subacute levels of suicidal ideation (C-SSRS 3 or 4, not requiring hospitalization) are randomized to receive twice daily oral NRX-101 or lurasidone (standard of care).

Eligibility criteria: Inclusion Criteria:

* Diagnosed with bipolar disorder by a qualified rater according to the criteria defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and supported by the Mini International Neuropsychiatric Interview (MINI) 7.0.2.
* Confirmed active suicidal ideation (without the intention to act) as evidenced by an answer of 'Yes' on item 3 and/or item 4 and not requiring hospitalization at Screening and an answer of "No" on item 5 of the C-SSRS.
* A total score greater than or equal to 30 on the 10 items of the MADRS.
* Subject has no co-morbidities as ascertained by medical history, physical examination (including measurement of vital signs), clinical laboratory evaluations, and electrocardiogram (ECG)

Exclusion Criteria:

* Subject has current DSM-5 diagnosis of moderate or severe substance use disorder (except marijuana or tobacco use disorder) within the 12 months prior to Screening.
* Subject has a lifetime history of:

  * phencyclidine (PCP)/ketamine drug abuse, or
  * failed use of ketamine for depression or suicidality.
* Subject has schizophrenia or schizoaffective disorder, or any history of psychotic symptoms when not in an acute bipolar mood episode.
* Subject has a current major psychiatric disorder, diagnosed at Screening
* Subject has been prescribed more than one agent in each of the following categories at randomization:

  * Approved SSRIs
  * Approved serotonin and norepinephrine reuptake inhibitors (SNRIs)
  * Approved tetracyclic antidepressants (TeCAs)
  * Approved Mood stabilizers (e.g., lithium, valproic acid, and lamotrigine)
* Subject has signs and symptoms of active or residual COVID-19, or unresolved symptoms of COVID-19 that impact health

Primary outcomes:
measure: Change from Baseline in MADRS-10 over 42 Days
timeFrame: Six weeks
Secondary outcomes:
measure: Mean Change from baseline in CGI-SS
timeFrame: Six Weeks
measure: Time to Treatment Failure
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Culver City
country: United States
facility: Science 37
state: California
city: Miami Lakes
country: United States
facility: San Marcus Research Clinic, Inc.
state: Florida
city: Atlanta
country: United States
facility: ACMR
state: Georgia
city: Decatur
country: United States
facility: iResearch Atlanta, LLC
state: Georgia
city: Savannah
country: United States
facility: iResearch Savannah
state: Georgia
city: Gaithersburg
country: United States
facility: CBH Health
state: Maryland
city: Omaha
country: United States
facility: Omaha Insomnia and Psychiatric Services
state: Nebraska
city: Amherst
country: United States
facility: Dent Neurologic Institute
state: New York
city: Eugene
country: United States
facility: Peace Health Medical Group
state: Oregon
city: Austin
country: United States
facility: University of Texas Health Austin
state: Texas
city: Austin
country: United States
facility: Roots Behavioral Health
state: Texas
city: Fort Worth
country: United States
facility: JPS Health
state: Texas
city: Houston
country: United States
facility: Houston Mind and Brain
state: Texas
city: Richmond
country: United States
facility: Health Texas
state: Texas
Study officials:
affiliation: NRx Pharma
name: Martin Brecher, MD
role: STUDY_DIRECTOR
affiliation: Harvard Medical School (HMS and HSDM)
name: Andrew A Nierenberg, MD
role: STUDY_CHAIR
affiliation: NRx Pharmaceuticals
name: Jonathan C Javitt, MD, MPH
role: STUDY_CHAIR
References: